FDA 483 - Precision Science Inc - June 21, 2019

An FDA inspection of Precision Science Inc. in Phoenix, AZ, from June 18-21, 2019, revealed a significant quality system deficiency. The firm failed to follow its own written procedures for evaluating batch records, specifically for the animal drug Protazil. This indicates a breakdown in adherence to established manufacturing controls.